IDH-mutant gliomas usually affect adults in their fourth and fifth decades of life; although they have a better prognosis compared to their IDH wild-type counterpart gliomas and glioblastomas, they remain incurable and the vast majority recur, hence the need for aggressive treatment. This evidence concerns the gene IDH2 and central nervous system cancer.